<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283698</url>
  </required_header>
  <id_info>
    <org_study_id>H553000-1005</org_study_id>
    <secondary_id>2010-022281-27</secondary_id>
    <nct_id>NCT01283698</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis</brief_title>
  <official_title>An Investigator-blind, Controlled Study to Assess the Efficacy of Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004
      in a Psoriasis Plaque Test (PPT)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in thickness of infiltration</measure>
    <time_frame>15 days</time_frame>
    <description>measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythema score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Induration score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scaling score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of skin reactions per patient as a measure of safety and tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>daily scoring will be performed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs per patients as a measure of safety and tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>reporting will be performed by investigator</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage 1, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage 2, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage 3, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: LAS 41004 dosage 1</intervention_name>
    <description>dosage 1, once daily</description>
    <arm_group_label>LAS 41004 dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: LAS 41004 dosage 2</intervention_name>
    <description>LAS 41004 dosage 2, once daily</description>
    <arm_group_label>LAS 41004 dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: LAS 41004 dosage 3</intervention_name>
    <description>dosage 3, once daily</description>
    <arm_group_label>LAS 41004 dosage 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Active Comparator,once daily</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Male or female patients between 18 and 75 years of age with a diagnosis of stable
             plaque-type psoriasis (psoriasis vulgaris) for at least 6 month

               -  Psoriasis plaques that are suitable to be defined as target area lesions by the
                  following criteria:

                    -  Psoriasis plaques must be located at trunk and/or extremities. Plaques that
                       are located on the head (incl. scalp), palms, sole of the feet,
                       intertriginous or genitoanal areas are not suitable as target areas

                    -  Comparable psoriasis plaques with at least &quot;2&quot; in each score (Range 0-4) for
                       the three distinct symptoms scaling; erythema; and induration

                    -  No more than 3 points difference in total score (= sum of scores for
                       scaling, erythema and induration; Range 0-12) of the chosen comparable
                       psoriasis plaques

                    -  Enough psoriatic surface area to define 5 clearly distinguishable (minimum
                       distance between test areas: 1cm) test areas of at least 1 cm² plaque size

               -  Patient is willing and able to comply with the requirements of the clinical study
                  protocol. In particular, patient must adhere SCIderm GmbH Confidential Almirall
                  Hermal GmbH Study protocol EudraCT No. 2010-022281-27 Protocol No. H553000-1005
                  Version 1.0 to concomitant therapy prohibitions of the test areas and must agree
                  to avoid intense UV exposure of the test areas during the study

               -  Written informed consent to participate in the study, prior to any study related
                  procedures, indicating an understanding of the purpose of the study

               -  A patient of childbearing potential agrees to use one of the following
                  contraceptive methods for the duration of the study and the following 4 weeks
                  after the end of study :

                    -  Strict abstinence (exception: male partner with a vasectomy for at least 3
                       months prior to study entry is allowed)

                    -  Combined oral, implanted or injectable contraceptives on a stable dose for
                       at least 3 months prior to study entrance

                    -  Intrauterine device (IUD) inserted for at least 1 month prior to study
                       entrance

        Exclusion Criteria:

          -  Too few body surface area covered with psoriasis plaques that meet the specified
             inclusion criteria to be defined as 5 clearly distinguishable test areas

          -  Any condition that may interfere with the study assessments or sonographic
             measurements of the skin and/or may have an influence on skin immune response (incl.
             open wounds)

          -  Known adverse reactions of any severity or hypersensitivity to any ingredient of the
             test products

          -  No willingness to avoid induction of heavy sweating, e.g. due to sauna visits,
             excessive sports activities during the study course

          -  No willingness to avoid swimming, bathing or wetting of the designated test areas
             between visits

          -  Pregnant or breast-feeding women

          -  A medical condition that may put the patient at a general risk and therefore would
             prevent participation in the clinical trial (including but not limited to: serious
             infectious diseases, major surgery within the last 4 weeks, coronary artery disease,
             renal impairment, hepatic impairment, uncontrolled metabolic diseases, disorders of
             the calcium metabolism, autoimmune diseases)

          -  History or presence of malignant disease (other than surgically removed basal cell
             carcinoma) and/or auto immune diseases

          -  Current diagnosis of guttate, erythrodermic or pustular psoriasis

          -  Patients who did not respect the following wash-out periods prior or during the study:

        Treatment Wash out period Topical treatment in the test area Any topical anti-psoriatic
        drug 2 weeks Systemic treatment Biologics 6 months Any other systemic treatment
        (corticosteroids, ciclosporin, MTX, fumaric acid esters) 3 months Procedures Phototherapy 4
        weeks

          -  Significant skin diseases other than plaque-type psoriasis (psoriasis vulgaris), incl.
             skin infections

          -  Excessive sunlight exposure within 28 days prior to study entry and during the conduct
             of the study

          -  Usage of any topical formulation (incl. cosmetics, emollients, etc) on the designated
             target areas during the course of the study

          -  Vaccination 6 days prior to enrolment or during the study

          -  Subjects who are - in the opinion of the investigator - unreliable, and/or
             non-compliant, and/or who present with any condition or treatment (including cosmetic
             products) that may interfere with psoriasis or the conduct of the trial

          -  Participation in any other clinical trial within 30 days prior or during this trial

          -  Subject is an adult under guardianship, hospitalised, deprived of freedom or unable to
             communicate or cooperate with the investigator due to language or mental problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Willers, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Almirall Hermal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.almirall.es/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>topical</keyword>
  <keyword>PPT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

